FDA Approves Merck’s WELIREG® (belzutifan) for the Treatment of Patients With Advanced Renal Cell Carcinoma (RCC) Following a PD-1 or PD-L1 Inhibitor and a VEGF-TKI
Also, WELIREG showed an objective response rate (ORR) of 22% (n=82) (95% CI, 18-27) versus 4% (n=13) (95% CI, 2-6) for everolimus.
- Also, WELIREG showed an objective response rate (ORR) of 22% (n=82) (95% CI, 18-27) versus 4% (n=13) (95% CI, 2-6) for everolimus.
- Patients could have received up to three prior treatment regimens and were required to have measurable disease per RECIST v1.1.
- Dose reductions of WELIREG due to an adverse reaction occurred in 13% of patients.
- Adverse reactions that required dose reduction in ≥1% of patients were hypoxia (5%) and anemia (3.2%).